Source:http://linkedlifedata.com/resource/pubmed/id/15620875
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-12-28
|
pubmed:abstractText |
The objectives of this study were to (1) characterize MDR-MDCK monolayers as an in vitro model to predict brain uptake potential; (2) examine the ability of MDR-MDCK monolayers to identify the brain uptake potential of compounds that interact with P-glycoprotein (P-gp). The study measured the bi-directional transport of 28 compounds across MDR-MDCK monolayers. The brain uptake of a subset of the compounds was determined in the rat brain perfusion model. Drug concentrations were analyzed by LC-MS-MS. CNS-positive drugs exhibited absorptive permeability coefficients (Papp, A-B) values ranging from 3.4 x 10(-6) to 20.2 x 10(-6) cm/s; whereas CNS-negative drugs showed Papp (A-B) ranging from 0.03 x 10(-6) to 0.83 x 10(-6) cm/s. Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compounds known to be P-pg substrates, but only enhanced the absorptive flux of compounds with high efflux ratio (>100). In vitro results were confirmed by brain perfusion studies on selected compounds. MDR-MDCK monolayers can be used to classify compounds into CNS-positive or CNS-negative based on the permeability coefficients (Papp, A-B). Under our experimental conditions, compounds with Papp (A-B)>3 x 10(-6) cm/s have high brain uptake potential; compounds with Papp (A-B)<1 x 10(-6) cm/s are unable to penetrate the blood-brain barrier (BBB); the brain uptake of compounds with Papp (A-B)<1 x 10(-6) cm/s and a P-gp-mediated efflux ratio of >100 may be enhanced by inhibiting P-gp.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0378-5173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
288
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-59
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15620875-Animals,
pubmed-meshheading:15620875-Blood-Brain Barrier,
pubmed-meshheading:15620875-Cell Line,
pubmed-meshheading:15620875-Dogs,
pubmed-meshheading:15620875-Male,
pubmed-meshheading:15620875-Permeability,
pubmed-meshheading:15620875-Pharmaceutical Preparations,
pubmed-meshheading:15620875-Rats,
pubmed-meshheading:15620875-Rats, Sprague-Dawley
|
pubmed:year |
2005
|
pubmed:articleTitle |
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
|
pubmed:affiliation |
Absorption Systems, 440 Creamery Way, Suite 300, Exton, PA 19341, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Evaluation Studies
|